MedTrace Logo

Alzheimer's in Long-Term Care--Treatment for Agitation

NCT00161473 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-08-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if a medication called prazosin is useful in the treatment of agitation and aggression in persons with Alzheimer's disease (AD) and other types of dementia in late life.

Conditions

  • Alzheimer Disease
  • Psychomotor Agitation

Interventions

DRUG

prazosin

Participants taking prazosin. Prazosin was administered as 1 or 2 mg capsules. Doses were initiated at 1 mg at bedtime. Titration based on tolerability was conducted up to a dose of 2 mg in the morning plus 4mg at bedtime. Duration was 8 weeks.

DRUG

placebo (inert substance)

Placebo is an inert substance used as a standard comparator in clinical pharmacologic trials. Duration is 8 weeks.

Sponsors & Collaborators

Principal Investigators

  • Elaine R Peskind, MD · Veterans Affairs Puget Sound Health Care System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00161473 on ClinicalTrials.gov